Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cannabidiol + tetrahydrocannabinol
- Development stage
- Phase 3
- Lead developer
- Seach Medical Group
- Modality
- Small Molecules
- Administration
- Sublingual
01
Overview
SH-03 is a sublingual oil formulation containing a 1:1 ratio of cannabidiol (CBD) and tetrahydrocannabinol (THC), developed by Seach Sarid (Seach Medical Group) for the treatment of diabetic neuropathic pain. The drug acts as a modulator of the endocannabinoid system, primarily targeting cannabinoid receptors CB1 and CB2 to alleviate neuropathic pain symptoms. SH-03 is being evaluated in Israel in a Phase IIa randomized, double-blind, placebo-controlled clinical trial in adults with type 2 diabetes mellitus who have inadequately controlled diabetic neuropathic pain despite prior standard therapies.
- Other names
- cannabidiol/tetrahydrocannabinolSH03SH-03SH 03tetrahydrocannabinol + cannabidiol
02
Targets
CNR1 (Cannabinoid receptor 1)GPR55 (G protein-coupled receptor 55)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on cannabidiol + tetrahydrocannabinol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cannabidiol + tetrahydrocannabinol.